# Nathan Peiffer‐Smadja

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nathan-peiffer-smadja/

## Facts

| Field | Value |
| --- | --- |
| Citations | 12,367 |
| Field | COVID-19 Clinical Research Studies |
| h-index | 38 |
| i10-index | 90 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5048207546 |
| ORCID iD | 0000-0003-1166-1958 |
| Works | 229 |

## Researcher papers

- [Autoantibodies against type I IFNs in patients with life-threatening COVID-19](https://scholariq.org/papers/autoantibodies-against-type-i-ifns-in-patients-with-life-threatening-covid-19/)
- [Inborn errors of type I IFN immunity in patients with life-threatening COVID-19](https://scholariq.org/papers/inborn-errors-of-type-i-ifn-immunity-in-patients-with-life-threatening-covid-19/)
- [Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review](https://scholariq.org/papers/comparing-covid-19-vaccines-for-their-characteristics-efficacy-and-effectiveness/)
- [Machine learning for clinical decision support in infectious diseases: a narrative review of current applications](https://scholariq.org/papers/machine-learning-for-clinical-decision-support-in-infectious-diseases-a/)
- [Type 1 interferons as a potential treatment against COVID-19](https://scholariq.org/papers/type-1-interferons-as-a-potential-treatment-against-covid-19/)
- [Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses](https://scholariq.org/papers/remdesivir-and-three-other-drugs-for-hospitalised-patients-with-covid-19-final/)
- [Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis](https://scholariq.org/papers/effect-of-hydroxychloroquine-with-or-without-azithromycin-on-the-mortality-of/)
- [Open science saves lives: lessons from the COVID-19 pandemic](https://scholariq.org/papers/open-science-saves-lives-lessons-from-the-covid-19-pandemic/)
- [Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians](https://scholariq.org/papers/neurological-manifestations-associated-with-sars-cov-2-and-other-coronaviruses-a/)
- [An analysis of existing national action plans for antimicrobial resistance—gaps and opportunities in strategies optimising antibiotic use in human populations](https://scholariq.org/papers/an-analysis-of-existing-national-action-plans-for-antimicrobial-resistance-gaps/)
- [Prior participation as a standardized patient improves OSCE scores of third-year medical students: A pilot comparative study at Université Paris Cité Medical School](https://scholariq.org/papers/prior-participation-as-a-standardized-patient-improves-osce-scores-of-third-year/)

## Researcher topics

- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [SARS-CoV-2 and COVID-19 Research](https://scholariq.org/topics/sars-cov-2-and-covid-19-research/)
- [Long-Term Effects of COVID-19](https://scholariq.org/topics/long-term-effects-of-covid-19/)
- [Antibiotic Use and Resistance](https://scholariq.org/topics/antibiotic-use-and-resistance/)
- [Pharmaceutical Practices and Patient Outcomes](https://scholariq.org/topics/pharmaceutical-practices-and-patient-outcomes/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.